secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARS Pharmaceuticals, Inc. (SPRY)
CIK:        0001671858
Form:       8-K
Filed at:   2022-09-02T23:59:59+00:00
Accession:  0001193125-22-237900
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Silverback terminates President/CSO and CFO; appoints interim CFO ahead of merger
--------------------------------------------------------------------------------

- Terminated Valerie Odegard (President/CSO) and Jonathan Piazza (CFO), effective Sept 2, 2022, to extend cash runway.
- Odegard and Piazza entered consulting agreements at $350/hour (max 20 hrs/wk) through merger close or Nov 30, 2022.
- Equity awards continue vesting during consulting period; options remain exercisable.
- Russ Hawkinson appointed Interim CFO; he also serves as SVP Finance and principal accounting officer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671858/000119312522237900/0001193125-22-237900-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671858/000119312522237900/d352338d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-237900

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer